Majority of cases presented as early stages, stage 0 to II. Age ranges of patients were 29 to 88 years. Overall 5 year survival for TNBC was 78.6%. Prevalence of BRCA mutation is 7.21% of the triple negative breast cancer cases.
Abstract. Aim: Triple–negative breast cancer has a poor prognosis due to its aggressive. Patients with 2+ IHC staining for HER2 underwent fluorescence in–
What is triple negative breast cancer? Who is at risk? Why is it so difficult to treat, and how can you treat it?
Stage 2 means the breast cancer is growing, but it is still contained in the breast or growth has only extended to the nearby lymph nodes. This stage is divided .
Higher rates of triple negative/basal-like tumors may explain, to some degree, the poor prognosis of breast cancers diagnosed in younger Black/non-Hispanic .
(74%), Her2 negative (93%), and grade 2 (48%; all p < 0.001). Endocrine. guideline recommendations for early stage breast cancer patients treated with APBI.